Fortrea (NASDAQ:FTRE - Get Free Report) posted its quarterly earnings results on Monday. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.09, Zacks reports. Fortrea had a negative net margin of 10.99% and a positive return on equity of 2.00%. The firm had revenue of $651.30 million for the quarter, compared to analyst estimates of $609.63 million. Fortrea updated its FY 2025 guidance to EPS.
Fortrea Stock Down 13.6%
Shares of FTRE traded down $0.84 during trading hours on Monday, hitting $5.32. The company had a trading volume of 2,088,251 shares, compared to its average volume of 1,699,580. The company's fifty day moving average price is $7.22 and its two-hundred day moving average price is $14.32. Fortrea has a one year low of $4.77 and a one year high of $29.32. The company has a market capitalization of $481.22 million, a PE ratio of -1.55, a price-to-earnings-growth ratio of 1.78 and a beta of 2.15. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.
Wall Street Analyst Weigh In
A number of research firms have commented on FTRE. Evercore ISI reduced their price objective on shares of Fortrea from $20.00 to $15.00 and set an "in-line" rating for the company in a research report on Tuesday, March 4th. The Goldman Sachs Group cut their price objective on shares of Fortrea from $22.00 to $11.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Mizuho dropped their target price on shares of Fortrea from $12.00 to $10.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Barclays restated an "underweight" rating and issued a $6.00 price target (down from $12.00) on shares of Fortrea in a research note on Thursday, April 10th. Finally, Robert W. Baird set a $12.00 price objective on shares of Fortrea in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a sell rating and eleven have issued a hold rating to the company's stock. According to data from MarketBeat.com, Fortrea has a consensus rating of "Hold" and a consensus price target of $15.82.
View Our Latest Stock Analysis on FTRE
About Fortrea
(
Get Free Report)
Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Featured Stories
Before you consider Fortrea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortrea wasn't on the list.
While Fortrea currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
